Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.

Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in ...

This review presents a comprehensive overview of the pathophysiology, epidemiology ... For example, rare, rheumatologic diseases (e.g., giant cell arteritis and polymyositis) may be simultaneously ...

Mortality rates among patients with GCA in Spain are similar to that of the general population, with older age and male sex linked to higher mortality.

Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release ...

Researchers’ understanding of the pathogenesis of rheumatoid arthritis has grown considerably in recent years, laying the ...

Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of the cardiovascular system including performing blood pressure measurements in both arms.

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...